Table 4. Comparison of glycan distribution for rituximab and RNA-mediated mAb.
| Glycans | Rituximab ± SD (%) | RNAi-mediated ± SD (%) |
|---|---|---|
| G0F | 34.2 ± 1.3 | 14.6 ± 0.8 |
| G0F-NGlc | 7.6 ± 0.6 | 2.3 ± 0.6 |
| G1F | 35.6 ± 2.7 | 4.2 ± 0.6 |
| G1F-NGlc | 4.7 ± 0.6 | 0.4 ± 0.1 |
| G2F | 9.6 ± 0.3 | 0.7 ± 0.1 |
| G0 | 2.8 ± 0.1 | 46.8 ± 1.6 |
| G0-NGlc | 1.2 ± 0.1 | 14.6 ± 2.1 |
| G1 | 0.9 ± 0.1 | 9.1 ± 0.6 |
| G1-NGlc | 0.1 ± 0.0 | 1.1 ± 0.1 |
| Man5 | 3.1 ± 0.1 | 5.0 ± 0.4 |
| Man4 | 0.1 ± 0.0 | 0.2 ± 0.1 |
| Man3 | 0.1 ± 0.0 | 0.9 ± 0.0 |
The percent glycosylation was obtained by the measured amount of the specific glycopeptide divided by the total of all forms of the glycopeptides including the non-glycosylated form. The SD was determined from 6 measurements.